Manufacturing costs loom large for personalized CAR-T cancer meds and their need for speed – FiercePharma
FiercePharma |
Manufacturing costs loom large for personalized CAR–T cancer meds and their need for speed
FiercePharma Novartis, in explaining its new CAR-T cancer drug candidate, says T cells like this are drawn from a patient's blood and reprogrammed in the laboratory so that they are genetically coded to hunt the patient's cancer cells and other B cells expressing a … |
